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Summary
We studied the HR2 haplotype of the factor V gene in a case-control
study for venous thrombosis including 474 patients with a first
deep-vein thrombosis and 474 age- and sex-matched healthy controls
(Leiden Thrombophilia Study, LETS). We investigated both the
original Hisl299Arg (A4070G) polymorphism and the Met385Thr
(T1328C) polymorphism. This latter polymorphism, located in exon 8
(heavy chain), is always present in the HR2 haplotype, but also occurs
on its own in a Hisl299 (wt) background. The HR2 haplotype was not
associated with an increased risk of venous thrombosis (OR = l .2,95%
confidence interval: 0.8-2.0). We did not find an association between
the HR2 haplotype and a reduced sensitivity for activated protein C
(APC) in non-carriers of factor V Leiden (FVL). However, in com-
pound heterozygous FVL/HR2 carriers the sensitivity for APC was re-
duced. The HR2 haplotype was also associated with reduced factor V
antigen levels in both patients and controls. Sequence analysis of the
Promoter region of factor V in HR2 homozygotes did not reveal any se-
quence variations that could explain the reduced FV levels. Our results
show that the HR2 haplotype is not associated with an increased risk of
venous thrombosis or with a reduced sensitivity for APC in non-FVL
carriers. However, the HR2 haplotype is associated with a reduced sen-
sitivity for APC in carriers of FVL and with reduced factor V antigen
levels.
Introduction
Human coagulation factor V (FV), which is synthesized in the liver
and in megakaryocytes, circulates in plasma äs a 330 kD single chain
glycoprotein. The domain organization (A1-A2-B-A3-C1-C2) of FV
is similar to that of factor VIII (FVIII) (1). By selective proteolytic
cleavages the large B-domain is removed, yielding activated FV (FVa)
which consists of a heavy chain (A1-A2) and a light chain (A3-C1-C2)
that are noncovalently linked by a calcium ion [for a review see Rosing
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and Tans (2)]. The activated FV molecule acts äs a cofactor to acti-
vated factor X (FXa) in the prothrombinase complex that proteolyti-
cally activates prothrombin to thrombin (3). FVa is inactivated by
activated protein C (APC) by selected proteolytic cleavages in the
heavy chain (4). This inactivation, with protein S äs cofactor, is an
important step in the anticoagulant pathway. Activated FVIII (FVIIIa)
is also inactivated by APC and FV is thought to function äs a cofactor,
synergistic with protein S, in this reaction (5-7).
Activated protein C resistance, a poor anticoagulant response of
plasma to APC, is almost always associated with the presence of a
mutation in one of the APC cleavage sites (Arg506) of FV (8, 9). The
activated FV variant (factor V Leiden, FVL) is inactivated more
slowly than activated wildtype FV (10-13). APC resistance caused by
the FVL mutation is a common and strong risk factor for venous throm-
bosis (14,15). Recently, we reported that a reduced sensitivity for APC
not due to FV Leiden is also associated with an increased risk of venous
thrombosis (16).
The gene for human FV is localized on chromosome lq23-24 and
consists of 25 exons and 24 introns (17). The B-domain is fully encod-
ed by the large exon 13. In 1996. the Hisl299Arg [A4070G. according
to the cDNA sequence of Jenny et al. (1)] polymorphism in exon 13 was
first described (18). In this study, the Arg 1299 (R2) allele was reported
to be more frequent in subjects with reduced FV activity levels. Subse-
quent studies which have investigated the HR2 haplotype have diverse
results. Bernardi et al. reported that the R2 allele was associated with
a reduced sensitivity for APC (19). An association with reduced FV
levels was not found in this Italian study, nor an indication that the R2
allele is a risk factor for venous thrombosis. A French case-control
study did show relationships between the HR2 haplotype and reduced
FV levels and a reduced response to APC (20). Besides. this study
showed that the R2 allele is associated with a 1.8-fold increased risk of
venous thromboembolism. One family study showed that compound
heterozygous FVL/HR2 carriers have a more reduced normalized APC-
SR than FVL heterozygotes (21). The HR2 haplotype includes. in addi-
tion to the R2 allele, 7 other polymorphisms in exon 13 and one in ex-
on 16. Fourof these variations do notcause aminoacid substitutions and
most of these polymorphisms have a much higher population frequen-
cy than the His 1299Arg Variation. The HR2 haplotype has an allele
frequency of 8% in Italians and of 6% in the French study (19,20).
We studied the HR2 haplotype in a population-based case-control
study on venous thrombosis (Leiden Thrombophilia Study, LETS). We
screened for the His 1299Arg polymorphism äs well äs for a novel Vari-
ation, the Met385Thr polymorphism. This latter polymorphism, which
was detected by sequencing of the FV gene of a FVL/HR2 compound
heterozygote, is also part of the HR2 haplotype and is located in the
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heavy chain of the FV molecule. Furthermore we investigated the asso-
ciation between the HR2 haplotype and FV antigen levels and the sen-
sitivity for APC. We also assessed the risk of venous thrombosis in
compound heterozygous carriers of the R2 allele and the FVL allele.
Patients and Methods
Subjecis
The Leiden Thrombophilia Study (LETS) is a population-based case-con-
trol study in three Dutch anticoagulation clinics. The study, of which the design
has been described extensively elsewhere (22), includes 474 patients with a fir.st
episode of deep venous thrombosis and 474 age- and sex-matched healthy con-
trol subjects. Venepuncture took place at least 6 months after the thrombotic
event. DNA analysis could be performed for 943 individuals (471 patients and
472 controls). For these individuals the ratio of male to female subjects was
l .3 for both patients and controls. The mean age was 47 years for both groups
(ränge 16-70 for the patients and 16-73 for the controls).
Blood CoIIeaion and Laboratory Anahsis
Blood was collected into tubes containing 0.106 mol/L tnsodium citrate.
Plasma was preparcd by centrifugation for 10 mm at 2000 g at room tempera-
ture and stored at -70° C. The sensitivity of the plasma activated partial throm-
boplastin time f APTT) to APC was measured äs described before (22). Results
were expressed äs normalized APC sensitivity ratios (n-APC-SR). The APC
sensitivity ratio is defined äs the APTT in the presence of APC divided by the
APTT in the absence of APC. The normalized APC-SR is calculated by divid-
mg the APC-SR of the sample by the APC-SR of pooled normal plasma which
is measured m the same run.
FV antigen (ag) was measured by a Sandwich type enzyme-linked immuno-
sorbent assay (ELISA) usmg two different monoclonal antibodies (V-6, V-9)
against the light chain of FV (23). Briefly, wells coated with monoclonal anti-
body V-6 were mcubated with diiuted plasma sample. Monoclonal antibody
V-9, conjugaled to horseradish peroxidase, was used for the detection of immo-
bilized FV. FVag levels were expressed in units per deciliter (U/dl). By dcfmi-
tion l ml pooled normal plasma contains l unil.
FVIIIag levels were measured by a Sandwich type ELISA with two different
monoclonal amibodies directed against the light chain of FVIII (Kamphuisen et
al., submitted). Briefly, wells coated with monoclonal antibody CLB Cag 117
were incubated with a diiuted plasma sample. Monoclonal antibody CLB-Cag
A conjugated to horseradish peroxidase was used for detection. Monoclonal
anti-FVIII antibodies were kindly provided by Dr J. van Mourik (CLB, Sanguin
Blood Supply Foundation, Amsterdam, The Netherlands).
FVIII coagulant activity (FVIII:C) was measured by a one-stage clotting
assay äs described before (24). Protein C activity and antithrombin activity
were measured with Coamate (Chromogenix, Mölndal, Sweden) on an
ACL-200 (Instrumentation Laboratory, Milan, Italy), factor II activity with a
chromogenic method using S-2238 (Chromogenix) and Echis carinatus snake
venom (Sigma Chemical Co, St Louis, USA) on an ACL-200 (25), and factor X
antigen was measured by ELISA with a polyclonal antibody (DAKO. Den-
mark) (de Visser et al., in preparation). Factor VII was measured using Throm-
borel S reagent (Behringwerke AG, Warburg, Germany) and factor VII defi-
cient plasma (Organon Teknica, Durham, USA) (26). Total protein S was
measured by polyclonal ELISA (27) and free protein S was measured directly
in plasma by ELISA using two monoclonal antibodies specific for free pro-
tein S (Asserachrom free protein S, Diagnostica Slago, Asnieres-sur-Seine,
France) (28, 29). The fibrinogen concentration was determined according to
method of Clauss using Dade® thrombin reagent (Baxter. Miami, USA) on an
Electra 1000 (MLA, Pleasantville, USA) (26).
The results of all the above mentioned measurcments, except for FVag,
FVIIIag and FXag have been reported previously (22, 24,26, 30).
High molecular weight DNA was isolated from leukocytes and stored at
4° C. A list of the primers used for sequencing of all exons of FV in the FVL/
HR2 heterozygote and a description of the sequencing procedure have been
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reported elsewhere (31). The detection of three polymorphisms (A4070G,
T1328C and A6755G; numbering according to Jenny et al. (1)) in the FV gene
was performed by polymerase chain reaction (PCR) followed by restriction
enzyme digestion. The PCR mixture consisted of 50 ng of both oligonucleo-
tides, 200 μΜ of each dNTP, 67 mM Tris-HCl pH 8.8,6.7 mM MgCl2,10 mM
ß-mercaptoethanol, 6.7 μΜ EDTA, 16.6mM (NH4)2S04, 0.5 mg/ml BSA,
0.2 units AmpliTaq polymerase (Perkin-Elmer) and 10% DMSO (only for the
A4070G and A6755G polymorphisms) in a total volume of l Ο μΐ. The reactions
were performed in a T3 Thermocycler (Biometra, Göttingen, Germany). The
PCR conditions were äs follows: 4 min initial denaturation at 94° C, followed
by 33 cycles of l min at 94° C, l min at 65° C and 90 sec at 72° C. A final
extension was performed at 72° C for 4 min. For detection of the A4070G
(= Hisl299Arg) polymorphism a 828 bp fragment was amplified with primer A
(5'-CATGAAGTCTGGCAGACAGTC-3') and primer B (5'-TATCTGGCT-
GAGATCCGGGAG-3'). The T1328C (= Met385Thr) polymorphism was
determined after amplification of a 153 bp fragment with primer C (5'-CAC-
CAAACATACAGTGAATCCCAGTA-3') and primer D (5'-AATAAC-
CAGGTACTCCATAATATTTTAC-3'). The underlincd nucleotide in primer
C corresponds to a mismatch with the gene sequence and was introduced to
create a Rsal restriction site (in the presence of the 1328C allele) for detection
of the polymorphism. For detection of the Asp2194Gly (= A6755G) polymor-
phism a 440 bp fragment was amplified with primers E (5'-GTGTTC-
TATGTGTTCTTTGATATCCTCATT-3') and F (5'-GGGTTTTTGAAT-
GTTCAATTCTAGTAGATA-3'). PCR products were digested by incubation
with either Rsal (New England Biolabs, A4070G and T1328C polymorphisms)
or with EcoRV (New England Biolabs, A6755G polymorphism) overnight at
37° C. The restriction fragments (A4070G polymorphism: 828 bp for the
4070A allele. and 381 and 447 bp for the4070G allele; T1328C polymorphism:
! 42 and 11 bp for the 1328T allele, and 117,25 and 11 bp for the 1328C allele;
A6755G polymorphism: 390, 29 and 21 bp for the 6755A allele, and 419 and
21 bp for the 6755G allele) were separated in 2% agarose gels and visualized
after cthidium bromide staining. The determination of the FVL mutation in the
LETS samples has been described previously (9). Almost 2 kb of the upstream
region of the FV gene (bases -l to -1933, according to GenBank sequence
U83346) was amplified by PCR with primers G (5'-TCAGTAGGC-
TAGGTGTTCTAGGAC-3') and H (5'-GCTTCCTTTCCTGCTCCCGC-3')
with the Expand Long Template PCR System (Boehringer Mannheim). Se-
quencing of this PCR fragment was performed with the ABI Prism® BigDye
terminator cycle sequencing ready reaction kit (Perkin-Elmer Applied Bio-
systems) according to manufacturer's protocol. Sequences of the used primers
can be asked for. The reactions were run on an ABI Prism 310 (Perkin-Elmer
Applied Biosystems).
Statistical Analysis
Odds ratios (OR) were calculated in the Standard unmatched fashion.
Ninety-five percent confidence mtervals (95% CI) were constructed according
to Woolf (32). The OR is used äs an estimate of the relative risk. which indi-
cates the risk of developing venous thrombosis in a category of exposure (e.g.,
HR2 carriers) relative to the reference category (e.g., HR2 wildtype). An OR of
l indicates no effect on risk, while an OR above l indicates an increase in risk.
Results
The Met385Thr Polymorphism
In the population-based case-control study LETS, one heterozygous
FVL carrier was present with a normalized APC-SR of 0.44. In our
laboratory this ratio is within the ränge of homozygous FVL carriers
(n-APC-SR <0.45) (33). Because of this discrepancy all exons of the
FV gene were sequenced in this individual. Besides the FVL muta-
tion and some previously described polymorphisms, the A4070G
(Hisl299Arg) Variation, which is part of the HR2 haplotype, was de-
tected in heterozygous form (19). Previous investigations had already
shown that the FVL allele is not present in the HR2 haplotype (34-37).
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Furthermore one novel Variation (T1328C, Met385Thr) in exon 8 was
detected. This latter Variation was not present in 8 homozygous FVL
carriers (Guasch et al., unpublished results), so the Thr385 allele is
not part of the FVL haplotype. Screening of a panel of 90 normal indi-
viduals for the Hisl299Arg and Met385Thr variations revealed 9 indi-
viduals who were heterozygous for both variations. Two individuals
were homozygous for Hisl299 and heterozygous for Met385Thr. So,
the Thr385 allele is always present in the HR2 haplotype, but can also
occcur on its own in a Bis 1299 (wildtype, Rl) background. Previous
studies (19, 20) have reported an association between reduced normal-
ized APC-SR and the presence of the HR2 haplotype, but no plausible
explanation for this reduction has been found yet. The Met385Thr
polymorphism is located in the heavy chain of FV, which is directly
involved in the generation of thrombin and the inactivation of FVa by
APC. Therefore we hypothesized that this Variation might be respon-
sible for the reduced normalized APC-SR. Because the two variations
Hisl299Arg and Met385Thr are not in absolute linkage disequilibrium,
we looked at both polymorphisms m LETS.
HR2 Haplotype and the Risk of Venous Thrombosis
All subjects were screened for both the Hisl299Arg (A4070G) poly-
morphism m the B-domain and the Met385Thr (T1328C) polymor-
phism in the heavy chain of FV (Table 1). It was found that 2 of the
471 patients were homozygous for the R2 allele and 46 were heterozy-
gous (allele frequency 5.3%). Thirty-nine of the 472 controls were het-
erozygous for the R2 allele and none of the controls was homozygous
for the R2 allele (allele frequency 4.1%). The odds ratio (OR), calculat-
ed äs a measure of the relative risk of venous thrombosis, for subjects
carrymg the R2 allele (in heterozygous or homozygous form) was 1.2
(95% CI: 0.8-2.0) compared to homozygous Rl (wildtype) carriers. In
addition to all carriers of the R2 allele, seventeen homozygous carriers
of the R l allele (8 patients and 9 controls) were heterozygous for
the Thr385 allele. The allele frequency for the Thr385 allele was 6.2%
and 5.1% for patients and controls, respectively. The Thr385 allele
was also not associated with an increased risk of venous thrombosis
(OR= 1.2, 95% CI: 0.8-1.8).
Compound Heterozygous HR2/Factor V Leiden Carriership
and Risk of Venous Thrombosis
We investigated whether co-mhentance of the R2 allele mflu-
enced the risk of venous thrombosis m heterozygous carriers of FVL
(Table 2). Homozygous FVL or HR2 carriers were not included m this
analysis because the FVL allele and the R2 allele are not present in the
same haplotype (37). The OR for heterozygous carriers of FVL who
are not carrying the R2 allele was 7.1 (95% CI: 3.9-13) compared to
wildtype camers (no HR2 and no FVL). The OR for compound hetero-
zygous FVL/HR2 carriers was slightly higher (OR = 11, 95% CI:
1.4-88), but the confidence intervals largely overlapped.
HR2 Haplotype and Normalized APC Sensitivity Ratio
We investigated the relationship between the HR2 haplotype and the
sensitivity for APC, which was measured in undiluted plasma by an
APTT-based assay with Cephotest® äs activator. The association
between genotype and normalized APC-SR is shown in Table 3. All
FVL homozygotes carried the Rl allele, because this allele is part of the
FVL haplotype. Compound heterozygous carriers for FVL/R2 have
reduced normalized APC-SRs compared to FVL/R1 carriers. In non-
Table l Frequencies of the His 1299Arg and Met385Thr polymorphisms
Hisl299Arg



















































Subjects homozygous for factor V Leiden (8 patients) or homoz\gous for the R2 aileie (2
patients) are not included m this table
Table 3 Mean noimahzed APC sensitivity ratio accordmg to tactor V Leiden
and the factoi V Hisl299Aig polymoiphism
Patients
FVL Hisl299Arg n n-APC-SR (95% CI)
+ + - - 8 0 43 (0 42 - 0 44)
+ - -- 63 0 3 7 ( 0 3 6 - 0 5 8 )
+ - S 0 5 1 ( 0 4 8 - 0 5 4 )
303 096(095 097)
+ - 32 0 95 (0 92 - 0 99)
+ + 2 0 92. 0 93
Controls
n n-APC-SR (95% CI)
0
13 0 5 7 ( 0 5 6 - 0 5 9 )
1 052
415 1 0 2 ( 1 0 1 - 1 0 4 )
'S 1 03 (0 98 - 1 08)
3
Patients usmg oral anticoagulants or \wth a lupus anticoagulam \\ere excluded for this analvsis
FVL carriers no difference in APC sensitivity was found between car-
riers of the R l allele and carriers of the R2 allele m both patient and
control groups. None of the 17 subjects who were only heterozygous
for Met385Thr did carry the FVL mutation. For both patients and con-
trols, no significant difference m mean normalized APC-SR was found
between this group and non-FVL carriers who were homozygous for
Rl/Met385.
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Patients Controls Table 4 Mean factor V antigen levels (U/dl) according to
the factor V Hisl299Arg polymorphism







HR2 Haplotype and Factor V Antigen Levels
The association between the HR2 haplotype and FVag levels was
investigated. The results are shown in Table 4. Mean FVag levels were
134 U/dl and 132 U/dl for patients and controls, respectively (23). The
R2 allele was associated with reduced FVag levels in both patients and
controls. To assess whether the reduction in FVag levels was specific
and not due to a difference in liver function, mean levels of other coag-
ulation factors were calculated for the different genotype subgroups.
For the investigated coagulation factors (FVIIIag, FVIII:C, antithrom-
bin, fibrinogen, factor II, factor VII, factor X, protein C, protein S [free
and total]) no differences in mean levels were found between homozy-
gous Rl carriers and heterozygous R1R2 carriers. To establish whether
the reduction m FV levels was caused by the Thr385 Variation we com-
pared the mean FV levels of subjects homozygous for Rl and Met385
(N = 839, mean FVag = 135 U/dl, 95% CI: 133-137) and subjects
homozygous for Rl but heterozygous for Met385Thr (N = 17, mean
FVag = 124 U/dl. 95% CI: 108-141). For this analysis patients and
controls were taken togethei because of the small size of the group of
subjects heterozygous for the Met385Thr vanant. Again, no difference
in mean FV levels was found. So, the established reduction in FV
levels in carriers of the HR2 haplotype is probably not due to the
Thr385 allele.
Promoter Polymorphisms
We wondered whether the reduced FV levels that were found in
carriers of the HR2 haplotype were caused by a polymorphism in the
Promoter region of FV in linkage disequilibrium with the R2 polymor-
phism. Therefore we sequenced 1933 basepairs of the promoter region
of FV of the two HR2 homozygotes and one wildtype control. No se-
quence variations were identified between the three sequenced individ-
uals. The sequences we found were identical to the PAC sequence sub-
mitted by Bird (GenBank accession number Z99572).
Hisl254Arg Polymorphism
During screening of the Hisl299Arg polymorphism, one aberrant
Rsal restriction pattern was detected, suggesting the presence of the
Hisl254Arg (A3935G) polymorphism in the FV gene which was previ-
ously described by Lunghi et al. (38). The presence of this Variation in
heterozygous form was confirmed by sequence analysis. Like the R2
polymorphism, the Hisl254Arg polymorphism is located in a highly re-
peated area of exon 13 with 31 tandem repeats of 27 bp. It is interesting
that the two polymorphisms are located in exactly the same position
(20th nucleotide) of two similar repeats (Hisl 254Arg in the 11 th repeat
and Hisl299Arg in the 16th repeat). The female control carrying this
variant had a normalized APC-SR of 0.78 and a FVag level of 117 U/dl,
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which is relatively low for the LETS population. She did not carry the
R2 allele or the Thr385 allele.
Asp2194Gly Polymorphism
Recently, a missense polymorphism (A6755G) in exon 25 of the FV
gene was reported, predicting an ammoacid Substitution (Asp2194Gly)
in the C2 domain of the FV molecule (39). This polymorphism was
found to be tightly linked to the R2 allele. We screened all carriers of
the R2 allele for this polymorphism and found that 2 of the 85 hetero-
zygous carriers did not carry this novel Variation. Two homozygous R2
carriers did carry the Gly2194 allele in homozygous form. Furthermore
this Variation in the light chain was not detected in 150 homozygous
Hisl299 carriers. We had not detected this Variation by sequence anal-
ysis of all FV exons of the compound heterozygous FVL/HR2 subject.
Re-analysis revealed the presence of the Asp2194Gly polymorphism in
heterozygous form. Our results confirm the tight linkage of this Varia-
tion to the R2 allele.
Discussion
The HR2 haplotype of the FV gene was not found to be associated
with an increased risk in our population-based case-control study for
venous thrombosis (LETS). These findings correspond with the results
of Bernardi and Luddington (19,40). Our results differ from the results
of a recent French study that did find an increased risk of venous throm-
bosis associated with the HR2 haplotype (20). The study population of
this French study was not exactly defmed, but allele frequencies of FVL
and the prothrombin G20210A variant in this French study were not
different from the frequencies in our study (15,20,41).
Faioni et al. recently showed in a family study that co-inheritance of
the R2 allele resulted in an increased risk of venous thromboembolism
in FVL carriers (42). Our data do not support this observation, but can-
not exclude it either. The OR for compound heterozygous FVL/HR2
carriers was slightly higher (OR = 11,95% CI: 1.4-88) than the OR for
heterozygous FVL carriers (OR = 7.1, 95% CI: 3.9-13), but the confi-
dence intervals largely overlapped. Because the OR for compound
heterozygotes depends on only one control, these data suffer from sta-
tistical uncertainty.
In addition to the Hisl299Arg polymorphism we studied the
Met385Thr polymorphism in the heavy chain of FV. This Variation,
that had not been previously reported, is part of the HR2 haplotype and
was detected by sequencing of a FVL heterozygote with an APC resist-
ant phenotype similar to a homozygous FVL carrier. In our large popu-
lation sample the Thr385 allele was always present in the HR2 haplo-
type, but it also occurred with the R l allele. Just like the R2 allele, the
Thr385 allele was not associated with an increased risk of venous
thrombosis.
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Recently, a missense polymorphism (A6755G) in exon 25 of the FV
gene was reported, predicting an aminoacid Substitution (Asp2194Gly)
in the C2 domain of the FV molecule (39). We confirmed the tight
linkage of this Variation to the R2 allele by screening of all R2 carriers
and 150 homozygous R l carriers. It was reported that in carriers of the
Gly2194 allele the ratio of the two isoforms of FV (FV1 and FV2) is
shifted in favor of FV1, the isoform which has the highest overall pro-
coagulant activity (39,43,44).
Our observation that the HR2 haplotype is associated with reduced
FV levels corresponds with the results of all previous studies on the
HR2 haplotype (18, 20, 21), except the study of Bernardi et al. (19). In
this Italian study FV levels were only measured in a small sample of
HR2 carriers and not in non-carriers. Our findings that the HR2 haplo-
type is associated with reduced FV levels but not with an increased risk
of venous thrombosis agrees with the recent finding that reduced FV
levels are not a risk factor for venous thrombosis (23). To assess wheth-
er the reduction in FV levels was due to the Thr385 allele we compared
mean FV levels of subjects homozygous for Rl and Met385 and sub-
jects homozygous for Rl but heterozygous for Met385Thr. No differ-
ence was found, so we showed that the Thr385 Variation in the heavy
chain is probably not responsible for the reduced FV levels in the HR2
haplotype. Another possible explanation for the reduced FV levels is
that the Hisl299Arg polymorphism is in linkage disequilibrium with a
polymorphism in the promoter region of the FV gene that may cause a
reduced expression of the FV gene. To investigate this we sequenced a
large upstream region (1933 bp) of two homozygous HR2 carriers and
one wildtype control, but no sequence variations were detected. So, the
mechanism by which the genotype is associated with reduced FV levels
is not clear yet. The most simple explanation is that the Hisl299Arg
variant itself is responsible for the reduction in FV levels. The Substitu-
tion of histidine to arginine at amino acid 1299, which is located in a
highly repeated region in exon 13 of the FV gene, will give a repeat
with a unique sequence and could be responsible for reduced FV levels
through the production of a less stable protein or interference with
intracellular trafficking. One indication for this explanation is that the
heterozygous carrier of the Hisl254Arg polymorphism, which is locat-
ed in homologous position in the repeat äs the Hisl299Arg mutation,
also has a relatively reduced FV level (l 17 U/dl).
In our study population the HR2 haplotype was not associated with
a reduced sensitivity for APC in non-FVL carriers. However, in com-
pound heterozygous FVL/HR2 carriers, the normalized APC-SR was
reduced compared to heterozygous FVL/R1 carriers. This observation
corresponds with the results of the family study of Castaman et al. (21).
It also corresponds with the results of previous reported plasma experi-
ments in which a mixture of homozygous HR2 plasma and homozy-
gous FVL plasma led to a reduced normalized APC-SR compared to
FVL heterozygous plasma (19). Our finding that the HR2 haplotype in
non-FVL carriers is not related with a reduced sensitivity for APC can
be shared with a recent French study in which the APC ratio, measured
with an APC resistance assay with undiluted plasma, in patients carry-
ing the R2 allele was not different from patients not carrying the allele
(20). In the control group of this latter study only a small difference in
APC ratio, measured with a modified FV specific assay, was found. In
the original study of Bernardi, who was the first to point to an associa-
tion between the HR2 haplotype and a reduced sensitivity for APC, this
relation was only proven in a small study population (19). The use of
different APC resistance tests can also be the cause of the discrepancies
between the above mentioned studies. The measured APC response de-
pends on the type of clotting lest and the particular reagent that is used.
Besides, the influence of other factors (e.g. FVIII levels), apart from
FVL, that determine the APC response may differ between assays
(16,45,46). The observation that the effect of the HR2 haplotype on the
normalized APC-SR is only found in FVL carriers can be explained by
the fact that the APC resistance assay reflects, among other things, the
ratio between the concentrations of the wildtype FV molecule and the
FVL molecule in plasma (9). The R2 allele is associated with reduced
FV levels and äs a result the relative concentration of the FVL molecule
increases, leading to a more reduced normalized APC-SR. More
gravely, this effect is observed in compound heterozygous carriers of
FVL and a quantitative FV deficiency (47-50). These so-called pseudo-
homozygous FVL carriers have reduced normalized APC-SRs within
the ränge of homozygous FVL carriers, due to the decrease in the rela-
tive concentration of the normal FV molecule.
We conclude that the HR2 haplotype is associated with reduced
FVag levels and with a reduced sensitivity for APC in FVL carriers. It
is not associated with a reduced sensitivity for APC in non-FVL car-
riers or with an increased risk of venous thrombosis. The mechanism
which underlies the reduction of FV levels has to be further investi-
gated.
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